BLENREP 70 MG
BELANTAMAB MAFODOTIN : 70 MG · DIN 02559617 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is BLENREP?
BLENREP 70 MG contains BELANTAMAB MAFODOTIN : 70 MG. It is listed in the Health Canada Drug Product Database under DIN 02559617, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BLENREP used for?
In combination with bortezomib/dexamethasone or pomalidomide/dexamethasone for relapsed or refractory multiple myeloma in adults who have received at least one prior therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02559617 |
|---|---|
| Brand name | BLENREP |
| Generic / active ingredient | BELANTAMAB MAFODOTIN : 70 MG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 70 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | L01FX15 BELANTAMAB MAFODOTIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Aug-2025 |
How is it administered?
IV infusion over 30 mins. With BVd: 2.5 mg/kg every 3 weeks. With BPd: Cycle 1: 2.5 mg/kg; Cycle 2+: 1.9 mg/kg every 4 weeks. Requires ophthalmic exams before each dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted: Refrigerated (2-8°C) or room temp (20-25°C) for up to 4 hours. Diluted: Refrigerated (2-8°C) for up to 24 hours; room temp for max 6 hours. Do not freeze.
How is it supplied?
Single-use vials containing 70 mg (blue cap) or 100 mg (orange cap) of belantamab mafodotin.
Contraindications
Hypersensitivity to belantamab mafodotin or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious Warning: Corneal epithelium changes (keratopathy) resulting in vision changes, dry eyes, or severe visual impairment. Requires frequent ophthalmic exams. Risk of thrombocytopenia.
What can be used instead?
Other Canadian products sharing ATC code L01FX15 BELANTAMAB MAFODOTIN. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BLENREP | 100 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02559625 |
Who else supplies BELANTAMAB MAFODOTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BELANTAMAB MAFODOTIN appears in 4 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.